- Home
- LNTH vs TLX Comparison
LNTH vs TLX Comparison
Compare LNTH & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNTH
- TLX
- Stock Information
- Founded
- LNTH 1956
- TLX 2015
- Country
- LNTH United States
- TLX Australia
- Employees
- LNTH N/A
- TLX N/A
- Industry
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- LNTH Health Care
- TLX Health Care
- Exchange
- LNTH Nasdaq
- TLX Nasdaq
- Market Cap
- LNTH 3.6B
- TLX 3.2B
- IPO Year
- LNTH 2015
- TLX N/A
- Fundamental
- Price
- LNTH $55.95
- TLX $10.96
- Analyst Decision
- LNTH Buy
- TLX Strong Buy
- Analyst Count
- LNTH 6
- TLX 4
- Target Price
- LNTH $74.50
- TLX $21.00
- AVG Volume (30 Days)
- LNTH 1.7M
- TLX 181.3K
- Earning Date
- LNTH 11-05-2025
- TLX 01-01-0001
- Dividend Yield
- LNTH N/A
- TLX N/A
- EPS Growth
- LNTH N/A
- TLX N/A
- EPS
- LNTH 3.77
- TLX 0.04
- Revenue
- LNTH $1,520,653,000.00
- TLX $664,225,558.00
- Revenue This Year
- LNTH N/A
- TLX N/A
- Revenue Next Year
- LNTH $2.91
- TLX N/A
- P/E Ratio
- LNTH $14.59
- TLX $235.46
- Revenue Growth
- LNTH 5.75
- TLX 55.35
- 52 Week Low
- LNTH $47.25
- TLX $8.93
- 52 Week High
- LNTH $118.21
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- LNTH 57.30
- TLX 59.07
- Support Level
- LNTH $52.21
- TLX $9.47
- Resistance Level
- LNTH $56.53
- TLX $10.28
- Average True Range (ATR)
- LNTH 1.65
- TLX 0.23
- MACD
- LNTH 0.80
- TLX 0.11
- Stochastic Oscillator
- LNTH 91.55
- TLX 81.92
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.